Tandutinib, also known as MLN519, is a type II tyrosine kinase inhibitor with activity against FLT3 (Clark et al, 2004; reviewed in Staudt et al, 2018; Daver et al, 2019). This pathway describes FLT3 mutants that are resistant to tandutinib-mediated inhibition.
Gilliland, DG, Lokker, NA, Curley, DP, Clark, JJ, Giese, NA, Yu, JC, Cools, J
Schlenk, RF, Levis, MJ, Daver, N, Russell, NH
Staudt, D, Murray, HC, Alvaro, F, Dun, MD, Enjeti, AK, McLachlan, T, Verrills, NM
© 2023 Reactome